On Friday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) was 3.41% up from the session before settling in for the closing price of $16.71. A 52-week range for ACAD has been $14.15 – $32.59.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 27.73% over the past five years. When this article was written, the company’s average yearly earnings per share was at 296.71%. With a float of $164.29 million, this company’s outstanding shares have now reached $166.35 million.
Let’s look at the performance matrix of the company that is accounted for 598 employees. In terms of profitability, gross margin is 91.61%, operating margin of 12.08%, and the pretax margin is 14.71%.
Acadia Pharmaceuticals Inc (ACAD) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Acadia Pharmaceuticals Inc stocks. The insider ownership of Acadia Pharmaceuticals Inc is 1.26%, while institutional ownership is 93.77%. The most recent insider transaction that took place on Nov 19 ’24, was worth 173,630. In this transaction EVP, COO, HEAD OF COMMERCIAL of this company sold 10,329 shares at a rate of $16.81, taking the stock ownership to the 62,105 shares. Before that another transaction happened on Nov 19 ’24, when Company’s PRINCIPAL ACCOUNTING OFFICER sold 4,073 for $16.81, making the entire transaction worth $68,467. This insider now owns 19,863 shares in total.
Acadia Pharmaceuticals Inc (ACAD) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 296.71% per share during the next fiscal year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
You can see what Acadia Pharmaceuticals Inc (ACAD) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.20. Likewise, its price to free cash flow for the trailing twelve months is 14.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.77, a number that is poised to hit 0.23 in the next quarter and is forecasted to reach 0.76 in one year’s time.
Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) saw its 5-day average volume 1.48 million, a negative change from its year-to-date volume of 1.66 million. As of the previous 9 days, the stock’s Stochastic %D was 81.47%. Additionally, its Average True Range was 0.61.
During the past 100 days, Acadia Pharmaceuticals Inc’s (ACAD) raw stochastic average was set at 59.17%, which indicates a significant decrease from 95.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.23% in the past 14 days, which was lower than the 49.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.71, while its 200-day Moving Average is $16.85. Nevertheless, the first resistance level for the watch stands at $17.52 in the near term. At $17.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $18.15. If the price goes on to break the first support level at $16.89, it is likely to go to the next support level at $16.49. The third support level lies at $16.26 if the price breaches the second support level.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Key Stats
There are 166,392K outstanding shares of the company, which has a market capitalization of 2.97 billion. As of now, sales total 726,440 K while income totals -61,290 K. Its latest quarter income was 250,400 K while its last quarter net income were 32,770 K.
